ym 529 has been researched along with raloxifene hydrochloride in 5 studies
| Studies (ym 529) | Trials (ym 529) | Recent Studies (post-2010) (ym 529) | Studies (raloxifene hydrochloride) | Trials (raloxifene hydrochloride) | Recent Studies (post-2010) (raloxifene hydrochloride) |
|---|---|---|---|---|---|
| 140 | 23 | 71 | 2,818 | 481 | 810 |
| Protein | Taxonomy | ym 529 (IC50) | raloxifene hydrochloride (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.0053 | |
| Gastric inhibitory polypeptide receptor | Homo sapiens (human) | 0.0004 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.1297 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakatoh, S | 1 |
| Fukunaga, M; Hagino, H; Miyazaki, T; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Sugimoto, T; Taguchi, A; Tanaka, S; Tsukiyama, M; Uemura, Y | 2 |
| Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z | 1 |
| Hagino, H; Mori, S; Nakamura, T; Ohta, H; Sone, T; Uemura, Y | 1 |
1 review(s) available for ym 529 and raloxifene hydrochloride
| Article | Year |
|---|---|
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D | 2020 |
4 trial(s) available for ym 529 and raloxifene hydrochloride
| Article | Year |
|---|---|
Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Middle Aged; Osteogenesis; Osteoporosis; Raloxifene Hydrochloride; Tartrate-Resistant Acid Phosphatase; Teriparatide; Vitamin D | 2018 |
Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Incidence; Osteoporotic Fractures; Raloxifene Hydrochloride; Sample Size; Spinal Fractures | 2019 |
Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Japan; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Raloxifene Hydrochloride; Treatment Outcome | 2020 |
Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.
Topics: Accidental Falls; Aged; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Multivariate Analysis; Osteoporosis; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures | 2021 |